Drugs /

tremelimumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
tremelimumab
NCI Definition [1]:
A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.

Clinical Trials

View Clinical Trials for tremelimumab

Tremelimumab has been investigated in 85 clinical trials, of which 68 are open and 17 are closed. Of the trials investigating tremelimumab, 2 are early phase 1 (2 open), 16 are phase 1 (9 open), 19 are phase 1/phase 2 (18 open), 41 are phase 2 (32 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open).

EGFR Exon 19 Deletion, EGFR L858R, and EGFR A763_Y764insFQEA are the most frequent biomarker inclusion criteria for tremelimumab clinical trials.

Non-small cell lung carcinoma, breast carcinoma, and fallopian tube carcinoma are the most common diseases being investigated in tremelimumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tremelimumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tremelimumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tremelimumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cp675,206, cp-675206, cp-675, anti-ctla4 human monoclonal antibody cp-675,206, cp 675, immunoglobulin g2, anti-(human ctla-4 (antigen)) (human monoclonal cp-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal cp-675206 clone 11.2.1 light chain, dimer, ticilimumab, cp-675,206, ticilimumab, cp675 cpd, immunoglobulin g2, anti-(human ctla-4 (antigen)) (human monoclonal cp-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal cp-675206 clone 11.2.1 light chain, dimer, anti-ctla4 human monoclonal antibody cp-675,206, cp675206, cp 675206, tremelimumab
Drug Categories [2]:
Anti-CTLA4 antibodies, Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
CTLA4
NCIT ID [1]:
C49085

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.